4Hovinga CA, Chicella MF, Rose DF, et al. Use of intravenous valproate in there pediatric patients with nonconvulisve or convulsive status epilepticus. Ann-Pharmacother, 1999, 33(5): 579-584.
5Wheless J, Vekafaraman V. Pharmacokinetics and safety of high dose rapid infusion of IV Valproic Acid (Depacon). J Epilepsy, 1998, 11(3): 319-324.
6Adin J, Arteaga R, Herranz JL, et al. The use of intravenous valproate Rev Neurol, 1999, 29(8): 744-753.
7Sinha S, Naritoku DK, Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology, 2000, 55(5): 722-724.
8Venkatarman V, Wheless JW. Safety of rapid intravenous infusion of valproate loadingdoses in epilepsy patients. Epilepsy Res, 1999, 35(2): 147-153.
9Krahenbuhl S, Brander S, Kleinle S, et al. Mitochondrial diseases represent a risk factor for acalproate-induced fulminant liver failure. Liver, 2000, 20(4): 346-348.
10Vossler DG, Wilensky AJ, Cawthon DF, et al. Serum and CSF glutamine levels in valproate-ralated hyperammonemic encephalopathy. Epilepsia, 2002, 43(2): 154-159.
